(0.32%) 5 116.24 points
(0.30%) 38 355 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.36%) $2.03
(0.30%) $2 354.20
(0.42%) $27.65
(4.15%) $960.35
(-0.27%) $0.932
(-0.44%) $10.98
(-0.58%) $0.796
(1.63%) $93.37
@ $27.40
発行日: 14 2月 2024 @ 23:30
リターン: 13.50%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: -0.36 %
Live Chart Being Loaded With Signals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States...
Stats | |
---|---|
本日の出来高 | 96 069.00 |
平均出来高 | 389 188 |
時価総額 | 1.70B |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $0.390 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 1 555.00 |
ATR14 | $0.0480 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Bhatt Padmanabh P. | Buy | 14 491 | Common Stock |
2024-03-21 | Bhatt Padmanabh P. | Sell | 14 491 | Employee Stock Option (Right to Buy) |
2024-03-21 | Bhatt Padmanabh P. | Sell | 14 491 | Common Stock |
2024-03-20 | Bhatt Padmanabh P. | Sell | 400 | Employee Stock Option (Right to Buy) |
2024-03-20 | Bhatt Padmanabh P. | Buy | 400 | Common Stock |
INSIDER POWER |
---|
38.23 |
Last 100 transactions |
Buy: 802 366 | Sell: 356 762 |
ボリューム 相関
Supernus Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
PCRX | -0.866 |
LLNW | -0.859 |
SFET | -0.848 |
NBRV | -0.842 |
MTEX | -0.834 |
IMTX | -0.831 |
ZENV | -0.831 |
SWAV | -0.829 |
DSPC | -0.827 |
RIVN | -0.825 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Supernus Pharmaceuticals 相関 - 通貨/商品
Supernus Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $607.52M |
総利益: | $438.88M (72.24 %) |
EPS: | $0.0241 |
FY | 2023 |
収益: | $607.52M |
総利益: | $438.88M (72.24 %) |
EPS: | $0.0241 |
FY | 2022 |
収益: | $667.24M |
総利益: | $580.02M (86.93 %) |
EPS: | $1.130 |
FY | 2021 |
収益: | $579.78M |
総利益: | $504.71M (87.05 %) |
EPS: | $1.010 |
Financial Reports:
No articles found.
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。